Dea-Della Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 21-12-2024
- Paid Up Capital ₹ 1.55 M
as on 21-12-2024
- Company Age 15 Year, 7 Months
- Last Filing with ROC 31 Mar 2019
- Open Charges ₹ 7.50 M
as on 21-12-2024
- Revenue -23.92%
(FY 2017)
- Profit -22.81%
(FY 2017)
- Ebitda 305.16%
(FY 2017)
- Net Worth 6.30%
(FY 2017)
- Total Assets -6.05%
(FY 2017)
About Dea-Della Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2019. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 1.55 M.
The company currently has active open charges totaling ₹7.50 M.
Gowthaman Chinnadorai, Hulikere Parameshwarappa, Govindappa Ramesh, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24232KA2009PTC049696
- Company No.
049696
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Apr 2009
- Date of AGM
30 Sep 2019
- Date of Balance Sheet
31 Mar 2019
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Dea-Della Life Sciences?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Gowthaman Chinnadorai  | Whole-Time Director | 29-Apr-2009 | Current |
| Hulikere Parameshwarappa | Whole-Time Director | 29-Apr-2009 | Current |
| Govindappa Ramesh | Whole-Time Director | 29-Apr-2009 | Current |
| Sedabavi Mahesh | Whole-Time Director | 29-Apr-2009 | Current |
| Chinnadorai Kumanan | Whole-Time Director | 29-Apr-2009 | Current |
Financial Performance of Dea-Della Life Sciences.
Dea-Della Life Sciences Private Limited, for the financial year ended 2017, experienced significant reduction in revenue, with a 23.92% decrease. The company also saw a substantial fall in profitability, with a 22.81% decrease in profit. The company's net worth moved up by a moderate rise of 6.3%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dea-Della Life Sciences?
In 2019, Dea-Della Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Dea Win Pharmaceuticals Private LimitedActive 3 years 8 monthsGowthaman Chinnadorai is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Development Credit Bank Limited Creation Date: 24 Nov 2012 | ₹5.00 M | Open |
City Union Bank Limited Creation Date: 06 Oct 2009 | ₹2.50 M | Open |
How Many Employees Work at Dea-Della Life Sciences?
Unlock and access historical data on people associated with Dea-Della Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dea-Della Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dea-Della Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
